CD22-Specific Antibodies for Selective B Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for autoimmune diseases often involve B cell depletion, which can lead to long-term suppression of B cell immunity and associated side effects. Additionally, natural regulatory mechanisms for B cell function can be dysfunctional in autoimmune diseases, necessitating alternative ways to modulate B cell activity.
Innovation Solution
Development of antibody molecules specific to CD22, which can be used alone or in combination with antibodies targeting other B cell surface receptors, to control aberrant B cell functions associated with autoimmune diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If B cell depletion is used to treat autoimmune diseases, then autoimmune and inflammatory events are reduced, but long-term suppression of B cell immunity and associated side effects occur
Solution Approach 1:
The patent segments the B cell population by targeting specific subsets expressing CD22 (such as activated B cells, germinal center B cells, or plasma cells) rather than depleting all B cells. This selective targeting allows reduction of pathogenic B cells while preserving protective B cell functions, resolving the contradiction between reducing autoimmune events and maintaining B cell immunity.
Solution Approach 2:
The patent uses CD22 as an intermediary marker to selectively identify and target specific B cell populations. By using CD22-specific antibodies as mediators, the therapy can distinguish between pathogenic and protective B cells, enabling selective depletion of harmful subsets while preserving immunity, thus resolving the contradiction between reducing autoimmune events and maintaining overall B cell function.
2Ease of operation
If natural regulatory mechanisms are left to function, then B cell activity is maintained, but in autoimmune diseases these mechanisms become dysfunctional leading to excessive B cell activation
Solution Approach 1:
The patent introduces an external feedback mechanism through CD22-specific antibodies that mimic or enhance the natural negative feedback loops (such as the Lyn/CD22/SHP-1 pathway) that normally regulate B cell activation. By providing this artificial feedback, the system can restore proper regulation in autoimmune diseases where natural feedback mechanisms are dysfunctional, resolving the contradiction between maintaining B cell function and preventing excessive activation.
3Adaptability or versatility
If alternative strategies to B cell depletion are used, then flexibility in controlling B cell function is improved, but the ability to effectively treat severe autoimmune conditions may be reduced
Solution Approach 1:
The patent employs dynamic control by using CD22-specific antibodies that can be administered at varying doses, frequencies, and combinations with other therapies. This dynamic approach allows clinicians to adjust the level of B cell suppression based on disease severity and patient response, providing flexibility while maintaining treatment effectiveness. The ability to modulate rather than completely deplete B cells enables tailored therapy that adapts to individual patient needs.
Data Source
AI summary
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.